AnalystBook Research · Company Intelligence

QUEST DIAGNOSTICS INC

DGXNYSE

Built from QUEST DIAGNOSTICS INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Quest Diagnostics paired double-digit growth with higher profit and free cash flow, while acquisitions and restructuring increased the burden on laboratory integration.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 11.8%OK
  • ProfitabilityNet income grew 13.9% to $992M from $871MOK
  • Cash flowFree cash flow grew 49.5% to $1.359B from $909MOK
  • MarginsOperating margin expanded 47 bps to 14.10%OK
  • AccountingStrong diagnostic growth with integration costsNote
  • Insiders0 purchases and 28 salesWatch

Business

Quest Diagnostics provides laboratory testing, diagnostic information and related services to patients, physicians, hospitals and health plans.

Where the revenue comes from

Fiscal 2025, as QUEST DIAGNOSTICS INC reports it. History and quarterly detail are in the app.

  • DIS business$10.8B
  • DS businesses$250.0M

Leadership changes

From QUEST DIAGNOSTICS INC's own filings, the day they're filed.

  • Timothy Wentworth · director · appointment
  • Walgreens Boots Alliance · director · appointment

Latest filings

  • 8-K · Company announcement2026-05-21
  • 8-K · Company announcement2026-05-08
  • 8-K · Company announcement2026-05-01
  • 10-Q · Quarterly report2026-04-22
  • 8-K · Company announcement2026-04-21
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about QUEST DIAGNOSTICS INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.